QQ客服 官方微博 反馈留言

	Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort.
	Wu, Lingying; Zhu, Jianqing; Yin, Rutie; Wu, Xiaohua; Lou, Ge; Wang, Jing; Gao, Yunong; Kong, Beihua; Lu, Xin; Zhou, Qi
	2019
会议名称	Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
会议日期	MAY 31-JUN 04, 2019
卷号	37
期号	15
DOI	10.1200/JCO.2019.37.15_suppl.5554
收录类别	CPCI-S ; SCIE
会议录	JOURNAL OF CLINICAL ONCOLOGY
URL标识	查看原文
内容类型	会议论文
URI标识	http://www.corc.org.cn/handle/1471x/6024709
专题	山东大学
作者单位	1.[Wu, LY 2.Zhu, JQ 3.Yin, RT 4.Wu, XH 5.Lou, G 6.Wang, J 7.Gao, YN 8.Kong, BH 9.Lu, X 10.Zhou, Q
推荐引用方式 GB/T 7714	Wu, Lingying,Zhu, Jianqing,Yin, Rutie,et al. Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort.[C]. 见:Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). MAY 31-JUN 04, 2019.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。